Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Tumor Markers Associated with H. Pylori Infection

By LabMedica International staff writers
Posted on 19 Sep 2018
Helicobacter pylori infection is a major cause of several cancers such as gastric, pancreatic and lung. More...
The relationship between H. pylori and tumor markers continues to remain unclear. As one of the leading causes of morbidity and mortality globally, cancer represents a major detrimental public health problem worldwide.

There are various known important tumor biomarkers in cancer progression such as carcinoembryonic antigen (CEA), cancer antigens (CA) 153, CA199, CA724, CA125 and alpha-fetoprotein (AFP) which have been shown in the past to have various evidence in diagnostic modalities. These tumor markers were reported to have a close relationship with specific cancers.

A team of scientists led by those at Aerospace Center Hospital (Beijing, China) carried out a observational retrospective study and recruited a total of 14,689 subjects were included and 6,493 (44.2%) subjects were infected by H. pylori. The subjects had a mean age of 45 ±18 years. There were 4,530 (31.0%) female subjects. H. pylori infection status was assessed by ELISA specific for anti-H. pylori antibodies, particularly IgG and IgM. If both serological testing results were positive, the subject was diagnosed as H. pylori infection.

Cut-off values were administered to distinguish whether tumor marker levels were normal or abnormal. According to previous studies, the cut-off values of serum CEA, AFP, CA199, CA724, CA153 and CA125 were set to 5 ng/mL, 10 ng/mL, 37 U/mL, 10 U/mL, 25 U/mL and 35 U/mL, respectively. The ratios of individual biomarkers were measured between the two groups. The ratio is defined according to the cut-off value. Abnormal ratio means the percentage of individuals with abnormal CEA (i.e., CEA>5 ng/mL) in total H. pylori (+) subjects or individuals with abnormal CEA in total H. pylori (−) subjects.

The scientists reported that after adjusting for the confounding factors, infections with H. pylori were found to be significantly associated with abnormal ratios in CEA, AFP and CA724 of H. pylori (+) to H. pylori (–) groups. Significant positive correlation was found between H. pylori infection and CEA values. Significant differences were found in both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels between H. pylori (+) and H. pylori (−) groups.

The authors concluded that in their observational retrospective study illustrated that higher abnormal ratios of CEA, AFP and CA724 were observed in infected to uninfected subjects. Higher level of CEA was also found to be related to H. pylori infection after controlling confounders. The serological testing for the presence of two antibodies against H. pylori, IgG and IgM, indicate a past exposure to this bacterium rather than a current exposure. These findings could aid in the earlier diagnosis and intervention provided to better patient’s quality of life. The study was published on August 23, 2018, in the journal BMJ Open.

Related Links:
Aerospace Center Hospital


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.